The present invention in general relates to the field of medical treatments and diagnostic markers, and more specifically to methods and uses for treatment of acute lymphocytic leukemia (ALL) which involve administration of a B-cell depleting agent. Uses and methods for conserving or increasing the number of long term survivors of ALL are also envisaged. The uses and methods provided herein comprise administration of a B-cell depleting agent and/or adjusting of the treatment regimen or dosage of the B-cell depleting agent so that the number of B-cells in the blood of the treated patients remains or falls below one B-cell/ml serum within a predefined period of time.
